The World Health Organisation (WHO) announced Tuesday that it will begin clinical trials November 1 in Switzerland of one of the two anti-Ebola vaccines currently under development. WHO Assistant Director-General Marie Paule Kieny said the reason that the trials set to be held at Lausanne Switzerland were important was that they include half of the total number of volunteers who would be given the vaccine. This will contribute to the correct determination of its safety and immunogenic properties in addition to establishing the required dosages for its use. One of the vaccines NIAD/GSK was developed in Britain by GlaxoSmithKline and